Core Viewpoint - Hualan Vaccine (301207.SZ) has received approval from the National Medical Products Administration for the clinical trial of its recombinant herpes zoster vaccine, indicating a significant step in the development of a new preventive measure against herpes zoster and its complications [1][2] Group 1: Company Developments - The company has developed a recombinant herpes zoster vaccine using CHO cells, which is designed to induce immune responses to reduce the risk of herpes zoster and related complications [2] - This vaccine represents an important strategic move for the company in the field of herpes zoster prevention, potentially providing new options for susceptible populations [2] Group 2: Industry Context - There are currently two herpes zoster vaccines available in the domestic market, indicating existing competition [2] - The demand for herpes zoster vaccination is expected to grow significantly due to the aging population and increased public health awareness, suggesting a broad market development prospect for domestic herpes zoster vaccines [2] - A recent epidemiological study indicated that the overall prevalence of herpes zoster in China is approximately 6.15%, with rates rising significantly with age, reaching 12.95% in individuals aged 70 and above [1]

Core Viewpoint - The announcement highlights that Zhifei Biological's subsidiary, Zhifei Longkema, has received the clinical trial application acceptance notice from the National Medical Products Administration for its recombinant herpes zoster vaccine ZFA01, which utilizes a novel adjuvant to enhance immune responses [1] Company Summary - Zhifei Biological's subsidiary, Zhifei Longkema, is developing the recombinant herpes zoster vaccine ZFA01 [1] - The vaccine is designed to prevent diseases caused by herpes zoster infection [1] - The new adjuvant developed by the company aims to stimulate both cellular and humoral immune responses, potentially improving the vaccine's protective efficacy [1] Industry Summary - The vaccine development is part of the broader pharmaceutical industry efforts to enhance vaccine effectiveness through innovative adjuvants [1] - The acceptance of the clinical trial application indicates progress in the regulatory pathway for new vaccine candidates in the market [1]